PP
GSK icon

PagnatoKarp Partners’s GSK GSK Stock Holding History

PagnatoKarp Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,228
Closed -$300K – 54
2020
Q1 		$300K Sell
6,228
-285
-4% -$15.2K 0.07% 125
2019
Q4 		$387K Hold
6,513
– – 0.07% 137
2019
Q3 		$351K Sell
6,513
-175
-3% -$9K 0.07% 139
2019
Q2 		$338K Buy
6,688
+781
+13% +$39.2K 0.07% 138
2019
Q1 		$313K Buy
5,907
+329
+6% +$16.4K 0.07% 131
2018
Q4 		$270K Sell
5,578
-720
-11% -$35.5K 0.06% 122
2018
Q3 		$320K Sell
6,298
-5,625
-47% -$286K 0.09% 125
2018
Q2 		$608K Sell
11,923
-3
-0% -$151 0.19% 72
2018
Q1 		$590K Buy
11,926
+572
+5% +$26.6K 0.25% 68
2017
Q4 		$511K Buy
11,354
+6,116
+117% +$283K 0.15% 89
2017
Q3 		$270K Buy
5,238
+588
+13% +$29.8K 0.07% 116
2017
Q2 		$253K Buy
4,650
+64
+1% +$3.41K 0.08% 112
2017
Q1 		$245K Buy
+4,586
New +$233K 0.07% 110

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PagnatoKarp Partners's GSK Position: Q2 2020 in Review

PagnatoKarp Partners sold out of GSK (GSK) in Q2 2020, closing a stake of 6,228 shares — an estimated $300K sold.

PagnatoKarp Partners first reported a position in GSK in Q1 2017 and held it in 13 quarters. The position peaked at $608K in Q2 2018. 841 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

  • PagnatoKarp Partners reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
  • PagnatoKarp Partners sold 6,228 GSK shares in Q2 2020, an estimated $300K.
  • PagnatoKarp Partners first reported a position in GSK in Q1 2017 and held it in 13 quarters.
  • PagnatoKarp Partners's GSK position peaked at $608K in Q2 2018.
  • 841 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.